File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1093/infdis/jiz223
- Scopus: eid_2-s2.0-85071350128
- PMID: 31056649
- WOS: WOS:000490985400004
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Plasma fibronectin levels identified via quantitative proteomics profiling predicts hepatitis B surface antigen seroclearance in chronic hepatitis B
Title | Plasma fibronectin levels identified via quantitative proteomics profiling predicts hepatitis B surface antigen seroclearance in chronic hepatitis B |
---|---|
Authors | |
Keywords | Biomarker Functional cure HBsAg HBV iTRAQ |
Issue Date | 2019 |
Publisher | Oxford University Press. The Journal's web site is located at http://jid.oxfordjournals.org |
Citation | The Journal of Infectious Diseases, 2019, v. 220 n. 6, p. 940-950 How to Cite? |
Abstract | Background:
Seroclearance of hepatitis B surface antigen (HBsAg) is a potentially achievable target of chronic hepatitis B (CHB). Plasma proteins relevant to HBsAg seroclearance remain undetermined.
Methods:
We prospectively recruited treatment-naive CHB patients with spontaneous HBsAg seroclearance and matched HBsAg-positive controls. Plasma protein profiling was performed using isobaric tags for relative and absolute quantitation-based proteomics, with the expression of candidate proteins validated in a separate cohort. The predictive value of fibronectin was assessed at 3 years, 1 year (Year -1) before, and at the time (Year 0) of HBsAg seroclearance.
Results:
Four hundred eighty-seven plasma proteins were identified via proteomics, with 97 proteins showing altered expression. In the verification cohort (n = 90), median plasma fibronectin levels in patients with HBsAg seroclearance was higher than in controls (P = .009). In the longitudinal cohort (n = 164), patients with HBsAg seroclearance, compared with controls, had a higher median fibronectin levels at Year -1 (413.26 vs 227.95 µg/mL) and Year 0 (349.45 vs 208.72 µg/mL) (both P < .001). In patients with an annual HBsAg log reduction >0.5, Year -1 fibronectin level achieved an area under the receiving operator characteristic of 0.884 in predicting HBsAg seroclearance.
Conclusions:
Using proteomics-based technology, plasma fibronectin may be associated with HBsAg seroclearance and a potential predictor of “functional cure”. |
Persistent Identifier | http://hdl.handle.net/10722/270088 |
ISSN | 2023 Impact Factor: 5.0 2023 SCImago Journal Rankings: 2.387 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Liu, F | - |
dc.contributor.author | Seto, WK | - |
dc.contributor.author | Wong, DKH | - |
dc.contributor.author | Huang, FY | - |
dc.contributor.author | Cheung, KS | - |
dc.contributor.author | Mak, LY | - |
dc.contributor.author | Sharma, R | - |
dc.contributor.author | Zhang, S | - |
dc.contributor.author | Fung, J | - |
dc.contributor.author | Lai, CL | - |
dc.contributor.author | Yuen, MF | - |
dc.date.accessioned | 2019-05-20T05:09:18Z | - |
dc.date.available | 2019-05-20T05:09:18Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | The Journal of Infectious Diseases, 2019, v. 220 n. 6, p. 940-950 | - |
dc.identifier.issn | 0022-1899 | - |
dc.identifier.uri | http://hdl.handle.net/10722/270088 | - |
dc.description.abstract | Background: Seroclearance of hepatitis B surface antigen (HBsAg) is a potentially achievable target of chronic hepatitis B (CHB). Plasma proteins relevant to HBsAg seroclearance remain undetermined. Methods: We prospectively recruited treatment-naive CHB patients with spontaneous HBsAg seroclearance and matched HBsAg-positive controls. Plasma protein profiling was performed using isobaric tags for relative and absolute quantitation-based proteomics, with the expression of candidate proteins validated in a separate cohort. The predictive value of fibronectin was assessed at 3 years, 1 year (Year -1) before, and at the time (Year 0) of HBsAg seroclearance. Results: Four hundred eighty-seven plasma proteins were identified via proteomics, with 97 proteins showing altered expression. In the verification cohort (n = 90), median plasma fibronectin levels in patients with HBsAg seroclearance was higher than in controls (P = .009). In the longitudinal cohort (n = 164), patients with HBsAg seroclearance, compared with controls, had a higher median fibronectin levels at Year -1 (413.26 vs 227.95 µg/mL) and Year 0 (349.45 vs 208.72 µg/mL) (both P < .001). In patients with an annual HBsAg log reduction >0.5, Year -1 fibronectin level achieved an area under the receiving operator characteristic of 0.884 in predicting HBsAg seroclearance. Conclusions: Using proteomics-based technology, plasma fibronectin may be associated with HBsAg seroclearance and a potential predictor of “functional cure”. | - |
dc.language | eng | - |
dc.publisher | Oxford University Press. The Journal's web site is located at http://jid.oxfordjournals.org | - |
dc.relation.ispartof | The Journal of Infectious Diseases | - |
dc.rights | This is a pre-copyedited, author-produced version of an article accepted for publication in The Journal of Infectious Diseases following peer review. The version of record The Journal of Infectious Diseases, 2019, v. 220 n. 6, p. 940-950 is available online at: https://doi.org/10.1093/infdis/jiz223 | - |
dc.subject | Biomarker | - |
dc.subject | Functional cure | - |
dc.subject | HBsAg | - |
dc.subject | HBV | - |
dc.subject | iTRAQ | - |
dc.title | Plasma fibronectin levels identified via quantitative proteomics profiling predicts hepatitis B surface antigen seroclearance in chronic hepatitis B | - |
dc.type | Article | - |
dc.identifier.email | Seto, WK: wkseto@hku.hk | - |
dc.identifier.email | Wong, DKH: danywong@hku.hk | - |
dc.identifier.email | Huang, FY: fungyu@hkucc.hku.hk | - |
dc.identifier.email | Cheung, KS: cks634@hku.hk | - |
dc.identifier.email | Mak, LY: lungyi@hku.hk | - |
dc.identifier.email | Sharma, R: rasharma@hku.hk | - |
dc.identifier.email | Fung, J: jfung@hkucc.hku.hk | - |
dc.identifier.email | Lai, CL: hrmelcl@hkucc.hku.hk | - |
dc.identifier.email | Yuen, MF: mfyuen@hku.hk | - |
dc.identifier.authority | Seto, WK=rp01659 | - |
dc.identifier.authority | Wong, DKH=rp00492 | - |
dc.identifier.authority | Cheung, KS=rp02532 | - |
dc.identifier.authority | Mak, LY=rp02668 | - |
dc.identifier.authority | Fung, J=rp00518 | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.identifier.authority | Yuen, MF=rp00479 | - |
dc.description.nature | postprint | - |
dc.identifier.doi | 10.1093/infdis/jiz223 | - |
dc.identifier.pmid | 31056649 | - |
dc.identifier.scopus | eid_2-s2.0-85071350128 | - |
dc.identifier.hkuros | 297818 | - |
dc.identifier.volume | 220 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | 940 | - |
dc.identifier.epage | 950 | - |
dc.identifier.isi | WOS:000490985400004 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0022-1899 | - |